Molecular Classification Based on the Gene Expression Profiles in Canine Histiocytic Sarcoma Cells

Hiroki Sakuma1, Hirotaka Tomiyasu1, Akiyoshi Tani1

  • 1Laboratory of Veterinary Internal Medicine, Department of Veterinary Medical Sciences, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Insights

Canine histiocytic sarcoma (CHS) molecular subtypes were identified using gene expression profiles. Two distinct clusters emerged, linked to NF-κB pathway activation, suggesting tailored precision medicine approaches for CHS treatment.

Area of Science:

  • Veterinary Oncology
  • Molecular Biology
  • Canine Cancer Research

Background:

  • Canine histiocytic sarcoma (CHS) molecular underpinnings are not fully understood.
  • Previous studies showed variable drug sensitivities among CHS cell lines, hinting at diverse molecular abnormalities.
  • Investigating these differences is crucial for developing effective treatments.

Purpose of the Study:

  • To classify canine histiocytic sarcoma (CHS) cell lines based on gene expression profiles (GEPs).
  • To identify molecular differences associated with distinct CHS subtypes.
  • To explore potential therapeutic strategies based on identified molecular pathways.

Main Methods:

  • RNA sequencing analysis of 11 CHS cell lines to generate GEPs.
  • Clustering analysis to group cell lines based on GEPs.
  • Differential gene expression analysis and RT-qPCR validation for key genes.
  • Examination of NF-κB pathway activation status (p65 nuclear translocation, CCL5 release).

Main Results:

  • CHS cell lines clustered into two distinct groups based on GEPs.
  • 675 differentially expressed genes (DEGs) were identified, enriched in inflammatory response pathways.
  • NF-κB pathway activation, indicated by p65 nuclear translocation and CCL5 release, distinguished one cluster.
  • No significant difference in Akt or ERK pathway activation was observed between clusters.

Conclusions:

  • Canine histiocytic sarcoma (CHS) exhibits molecular heterogeneity, potentially classifiable into two subtypes based on NF-κB pathway activation.
  • These findings support the development of precision medicine tailored to specific molecular subtypes of CHS.
  • Further research into these subtypes could lead to more targeted and effective therapeutic interventions.